|
Daehan New Pharm Launches ‘Spo-K Plaster’ for Arthritis Treatment
2004.12.02
|
|---|
|
Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has newly launched 'Spo-K Plaster,' an arthritis and muscle pain treatment containing menthol, thereby entering the patch market. Each patch contains 30 mg of ketoprofen and features an added L-menthol component, providing a cooling sensation immediately upon application. Spo-K uses a non-irritating breathable nonwoven fabric, making it safe for patients with sensitive skin, and its enhanced adhesive technology ensures it adheres well to curved areas such as the knees and elbows. The innovative adhesive technology improves adhesion and significantly reduces the problem of edges curling, common in conventional products.
Utilizing advanced Transdermal Drug Delivery System (TDDS) technology, the product targets pain areas directly, avoiding systemic side effects like liver toxicity and gastrointestinal disorders associated with oral administration. The current anti-inflammatory and analgesic patch market is dominated by Ketotop Plaster from Taepyeongyang Pharmaceutical and Kephentek Plaster from Jeil Pharmaceutical, forming approximately a 45 billion KRW market in 2005. Daehan New Pharm's new entry with Spo-K Plaster is expected to actively seek expansion in this market.
Through this launch, Daehan New Pharm aims to revitalize the stagnating OTC market with diverse marketing strategies, enhance consumer recognition, and strengthen pharmacy sales. The company plans to balance herbal medicines and Western OTC products as part of their product strategy, using this opportunity as a springboard for invigorating pharmacy operations. |


Home